Related references
Note: Only part of the references are listed.Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Aaron C. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer
Aakash Desai et al.
LUNG CANCER (2022)
Targeting un-MET needs in advanced non-small cell lung cancer
Niamh Coleman et al.
LUNG CANCER (2022)
Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach
S. Marks et al.
LUNG CANCER (2022)
Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
S. Lu et al.
ANNALS OF ONCOLOGY (2022)
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Laura Bonanno et al.
BRITISH JOURNAL OF CANCER (2022)
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib
D. Ross Camidge et al.
CLINICAL LUNG CANCER (2022)
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC.
Alexander E. Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
B.C. Cho et al.
ANNALS OF ONCOLOGY (2022)
Tepotinib plus osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
J. Mazieres et al.
ANNALS OF ONCOLOGY (2022)
EP08.02-138 SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
S. Lu et al.
Journal of Thoracic Oncology (2022)
EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
M-j. Ahn et al.
Journal of Thoracic Oncology (2022)
Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
H. Horinouchi et al.
ANNALS OF ONCOLOGY (2022)
Cabozantinib for the treatment of solid tumors: a systematic review
Pablo Maroto et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
Saiama N. Waqar et al.
CLINICAL LUNG CANCER (2021)
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer
Jin-Ji Yang et al.
INVESTIGATIONAL NEW DRUGS (2021)
Crizotinib in Patients With MET-Amplified NSCLC
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation A case report
Ruo-Yan Qin et al.
MEDICINE (2021)
Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
N. B. Leighl et al.
ANNALS OF ONCOLOGY (2021)
ORCHARD osimertinib plus savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
H. A. Yu et al.
ANNALS OF ONCOLOGY (2021)
Savolitinib: First Approval
Anthony Markham
DRUGS (2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
John O. DaSilva et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu et al.
LANCET RESPIRATORY MEDICINE (2021)
A rapid and durable response to cabozantinib in an osimertinib- resistant lung cancer patient with MET D1228N mutation: a case report
Yukun Kuang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns
Jessica K. Lee et al.
JCO PRECISION ONCOLOGY (2021)
Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro et al.
NATURE CANCER (2021)
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2020)
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC
Gonzalo Recondo et al.
CLINICAL CANCER RESEARCH (2020)
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
Giorgio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients
Patricia Mondelo-Macia et al.
CELLS (2020)
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
Hongge Liang et al.
ONCOTARGETS AND THERAPY (2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi-Long Wu et al.
LANCET RESPIRATORY MEDICINE (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Ravi Salgia et al.
CANCER TREATMENT REVIEWS (2020)
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Andrew J. Piper-Vallillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Smruthi Vijayaraghavan et al.
MOLECULAR CANCER THERAPEUTICS (2020)
The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton et al.
NATURE (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations
Vincent K. Lam et al.
CLINICAL LUNG CANCER (2019)
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib
Samantha X. Y. Wang et al.
ANTI-CANCER DRUGS (2019)
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed et al.
CLINICAL CANCER RESEARCH (2019)
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
Mark M. Awad et al.
LUNG CANCER (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK plus Lung Cancer
Leora Horn et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population
Yunjian Pan et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies
Jingyu Cao et al.
ONCOLOGIST (2019)
Current and future perspectives of liquid biopsies in genomics-driven oncology
Ellen Heitzer et al.
NATURE REVIEWS GENETICS (2019)
Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR-Mutation Testing in NSCLC Patients: a Pooled Analysis
Francesco Passiglia et al.
CURRENT CANCER DRUG TARGETS (2018)
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis
Huy Gia Vuong et al.
LUNG CANCER (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients
Clotilde Descarpentries et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Karie Runcie et al.
MOLECULAR MEDICINE (2018)
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
Hannah L. Williams et al.
VIRCHOWS ARCHIV (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing
Y. C. Zhu et al.
ANNALS OF ONCOLOGY (2018)
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
Dennis Plenker et al.
CLINICAL CANCER RESEARCH (2018)
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists
Lawrence J. Jennings et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Alexis B. Cortot et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels
Brigitte Poirot et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases
Samuel J. Klempner et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana et al.
LUNG CANCER (2017)
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Alexis B. Cortot et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Phase 1/2 Study of Rilotumumab (AMG 102), a Hepatocyte Growth Factor Inhibitor, and Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
Ahmad A. Tarhini et al.
CANCER (2017)
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer
Fred R. Hirsch et al.
CLINICAL LUNG CANCER (2017)
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non Small-Cell Lung Cancer
Heather Wakelee et al.
CLINICAL LUNG CANCER (2017)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Joel W. Neal et al.
LANCET ONCOLOGY (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H. Yoshioka et al.
ANNALS OF ONCOLOGY (2015)
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
David Casadevall et al.
ONCOTARGET (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
Elizabeth C. Smyth et al.
ONCOTARGETS AND THERAPY (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer
Giorgio V. Scagliotti et al.
CLINICAL LUNG CANCER (2012)
c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas
Koji Tsuta et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Heounjeong Go et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Target-enrichment strategies for next-generation sequencing
Lira Mamanova et al.
NATURE METHODS (2010)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
Ryoichi Onozato et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Expression and Mutational Analysis of MET in Human Solid Cancers
Patrick C. Ma et al.
GENES CHROMOSOMES & CANCER (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Determinants of RNA Quality from FFPE Samples
Silke von Ahlfen et al.
PLOS ONE (2007)
Characterization of the effect of sample quality on high density oligonucleotide microarray data using progressively degraded rat liver RNA
Karol L. Thompson et al.
BMC BIOTECHNOLOGY (2007)
RNA expression analysis of formalin-fixed paraffin-embedded tumors
Shannon K. Penland et al.
LABORATORY INVESTIGATION (2007)
Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor
E Gherardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Chromosome aberrations in solid tumors
DG Albertson et al.
NATURE GENETICS (2003)
DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line
AWI Lo et al.
NEOPLASIA (2002)
A role for common fragile site induction in amplification of human oncogenes
A Hellman et al.
CANCER CELL (2002)
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
P Peschard et al.
MOLECULAR CELL (2001)
Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer
MS Tsao et al.
HUMAN PATHOLOGY (2001)
Share Paper
